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Vascular endothelial growth factor (VEGF) – a stimulus of angiogenesis – is produced by epidermal keratinocytes,
and elevated levels have been found in plaques of psoriasis. Polymorphisms in the VEGF gene regulate production
of VEGF. We postulated that patients with psoriasis may have altered systemic expression of VEGF consequent
upon programming at the genomic level. We investigated the genetic basis of VEGF expression in patients with
type 1 (onset before age 40 y) chronic plaque psoriasis compared to healthy controls and also measured plasma
levels of VEGF and its receptors flt-1 and KDR. Patients with severe disease, and those with onset of psoriasis
between the ages of 20 and 40 y showed signiﬁcantly increased frequency of the þ 405 CC genotype (p¼ 0.04 and
p¼ 0.02) and the C allele (p¼ 0.03 and p¼ 0.02), respectively, compared to healthy controls. Plasma levels of VEGF
and flt-1 were signiﬁcantly detectable in patients with psoriasis compared with controls (po0.001); by contrast,
mean plasma levels of KDR in psoriatic patients were comparable with controls. These results suggest that
alterations in the biology of VEGF may be involved in the pathogenesis of psoriasis. VEGF, flt-1, and KDR could
provide attractive targets for future psoriasis therapy.
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Psoriasis occurs in 1 to 2% of the population and in early-
onset disease, onset before age 40 (Henseler and Christo-
phers, 1985), is genetically predetermined in conjunction
with environmental triggers. Several putative and confirmed
genetic loci for psoriasis have been reported as a result of
genome scanning. The locus of strongest effect appears to
be on chromosome 6p.21, in a region telomeric to HLA-C,
and has been designated PSORS 1 (Trembath et al, 1997;
Nair et al, 2000). The key histologic events in a plaque of
psoriasis include abnormal keratinocyte proliferation and
differentiation, inflammation, and vascular expansion (Grif-
fiths and Voorhees, 1996; Creamer et al, 1997). Micro-
vascular changes within plaques of psoriasis include
dilatation, tortuosity, increased permeability, and endothelial
cell proliferation within the venous limb of capillaries in the
dermal papillae (Braverman and Yen, 1977; Braverman and
Sibley, 1982). Vascular proliferation in psoriasis is in part
influenced by angiogenic factors produced by the epidermis
(Malhotra et al, 1989; Barnhill et al, 1984); these include
vascular endothelial growth factor (VEGF)/vascular perme-
ability factor (Thomas, 1996).
Angiogenesis is a common component of several
pathogenic mechanisms including tumor growth and
metastasis (Ferrara et al, 1992; Schott and Morrow, 1993;
Senger et al, 1993; Neufeld et al, 1994), inflammatory joint
disease (Brenchley, 2000), atheroma formation, and psor-
iasis (Detmar et al, 1994). The role of VEGF as a primary
angiogenic mediator has been confirmed in experimental
models of angiogenesis (Kim et al, 1993) and is now under
investigation in clinical disease (Ferrara, 1999). To date, the
majority of clinical studies have focused on VEGF in relation
to tumor angiogenesis and VEGF expression detected by
immunostaining in cancer of the breast (Toi et al, 1994),
colon (Takahashi et al, 1995), stomach (Maeda et al, 1996),
and esophagus (Inoue et al, 1997). Recent studies suggest
that circulating plasma levels of VEGF are 10 times higher
than normal in patients with ovarian carcinoma (Santin et al,
1999) and might be associated with extent of tumor
angiogenesis in hepatocellular carcinoma (Jinno et al,
1998). These results suggest that levels of VEGF in plasma
may act as a surrogate marker of pathological angiogen-
esis. VEGF is one of the most potent angiogenic factors
secreted both by tumor cells and tumor-invading macro-
phages in response to hypoxia and other cytokines (Dolecki
and Connolly, 1991; Detmar et al, 1997). It is an endothelial
cell mitogen and survival factor that binds to specific
receptors flt-1 (VEGFR1) and kinase insert domain receptor
(KDR; VEGFR2) thereby triggering signal transduction
pathways that mediate vascular angiogenesis and perme-
ability (Neufeld et al, 1999).
We have previously demonstrated that VEGF and
another angiogenic factor, endothelial cell-stimulating an-
giogenesis factor, are significantly elevated in plaques of
Abbreviations: PASI, psoriasis areas severity index; SNP,
single-nucleotide polymorphism; VEGF, vascular endothelial
growth factor.
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psoriasis and that these levels appear to correlate with
clinical severity of psoriasis (Bhushan et al, 1999). Further-
more, elevated levels of VEGF are present in the plasma of
patients with erythrodermic psoriasis (Creamer et al, 1996;
Creamer et al, 2002). The gene for VEGF is located on
chromosome 6p.21 (Vincenti et al, 1996; Mattei et al, 1996),
close to PSORS 1 (Trembath et al, 1997; Nair et al, 2000).
The VEGF gene is polymorphic with at least 15 single-
nucleotide polymorphisms (SNPS) described (Watson et al,
2000; Brogan et al, 1999; Renner et al, 2000). Two of these,
a C ! T at 460 (Genebank Accession No. RS833061) in
the promotor region and a G ! C at þ 405 (Genebank
Accession No. RS2010963), in the 50-untranslated region (50
UTR) are useful for association studies as they occur at
highest frequency in this area of the gene and have been
implicated as candidate SNP in other diseases with a
putative angiogenic basis (Awata et al, 2002).1–3 A sig-
nificant correlation has been observed between VEGF
protein production and the polymorphism, þ 405, within
the 50-UTR of the VEGF gene in healthy subjects (Watson
et al, 2000).
We postulated that patients with psoriasis may have
altered systemic expression of VEGF consequent upon
programming at the genomic level and that regulation of
VEGF protein expression may be related to disease severity.
We investigated the genetic basis of VEGF expression in
160 well-characterized patients with early onset, type 1,
chronic plaque psoriasis by measuring the frequencies of
the VEGF polymorphisms 460 C ! T (Genebank Acces-
sion No. RS833061) and þ 405 G ! C (Genebank Acces-
sion No. RS2010963) and observed whether this correlated
with plasma levels of VEGF, VEGF receptors, and clinical
severity of disease.
Results
A total of 160 patients with type 1 chronic plaque psoriasis
of a range of clinical severities were recruited to the study.
Twenty-three patients were then excluded from further
analysis on the basis of systemic treatments for psoriasis in
the 3 mo before the study and/or a diagnosis of psoriatic
arthropathy. The final patient group consisted of 68 men
and 69 women, with a median age of 38 y (range, 16–80 y),
a median age of psoriasis onset of 18 y (range, 0–39 y), and
a median PASI of 12.2 (range, 1.8–32.4). Sixty-five percent
(89 of 137) of patients had a family history of psoriasis and
63.5% (87 of 137) of patients had psoriatic nail involvement.
There were no significant differences in genotype
frequencies at the 460 or þ 405 sites when comparing
all psoriasis patients (n¼ 137) with controls (n¼ 102; Tables
I, II). Nevertheless, when patients were subgrouped on the
basis of disease severity those with severe disease (defined
as PASIX12; n¼ 72) showed significantly increased fre-
quency of the þ 405 CC genotype (chi-square test,
p¼0.04) compared to healthy controls (Table I). Overall C
allele frequency was also significantly increased—as ex-
pected given an increase in the observed frequency of the
CC genotype (chi-square test, p¼0.03). Patients with onset
of psoriasis between the ages of 20 and 40 y (n¼56) also
showed significantly increased frequency of the þ405 CC
genotype (chi-square test, p¼0.02) and, as a related
phenomenon, the C allele (chi-square test, p¼0.02)
compared to healthy controls (Table I). In addition, patients
with onset of psoriasis between the ages of 20 and 40 y
(n¼56) showed significantly reduced frequency of the
460 CC genotype (chi-square test, p¼ 0.02; Table II).
Comparison of patients with ‘‘severe’’ and ‘‘mild/moder-
ate’’ psoriasis revealed no significant genotype differences.
However, when patients with psoriasis onset at less than
20 y of age were compared with patients with psoriasis
onset after 20 y of age there was significantly reduced
frequency of the –460 CC genotype for the older onset
group (chi-square test, p¼ 0.01) and significantly increased
frequency of the TC genotype for the older onset group (chi-
square test, p¼0.03; Table II), with no significant differ-
ences in observed genotype frequencies for the þ 405
polymorphism (Table I). Fifty-eight percent of the psoriasis
patient group were Cw6-positive, and no linkage disequili-
brium was observed between either the þ405 or the 460
VEGF polymorphisms and HLA-Cw6 (chi-square test).
Levels of VEGF, flt-1, and KDR in plasma (Webb et al,
1998) were analyzed in 135 patients; two further patients
were excluded on the basis of concurrent use of COX-1 and
COX-2 nonsteroidal anti-inflammatory drugs that can inhibit
angiogenesis by blocking VEGF-induced signal transduc-
tion (Jones et al, 1999; Brenchley, 2000). Expression of
VEGF protein and flt-1 receptor in the plasma of healthy
volunteers was uncommon with only 24 and 11%, respec-
tively, having measurable levels. In patients with psoriasis
(n¼135), 98% had measurable expression of VEGF and
100% had detectable flt-1 in plasma which was significant
(chi-square test, po0.001). The mean levels of VEGF in the
plasma of all psoriasis patients and all normal controls were
43.03 (SD, 52.35; range, 0–462) and 14.6 pg per mL (range,
0–115), respectively. The mean plasma level of flt-1 in all
psoriatic patients was 31.1 pg per mL (SD, 13.0; range,
9–74), and the mean plasma level of flt-1 in all normal
controls 5.2 pg per mL (range, 0–73.6). In contrast, plasma
levels of KDR were equally detectable in patients and
controls with a mean plasma level of 8762 pg per mL (SD,
1759; range, 4,650–14,480) in all patients with psoriasis and
9577 pg per mL (range, 6,635–13,553) in controls.
Plasma levels of VEGF, flt-1, and KDR did not correlate
with psoriasis severity. Nevertheless, there was a weak but
significant correlation between plasma flt-1 and KDR
receptor levels in all patients with psoriasis (r¼ 0.2,
p¼0.02, one-tailed). There were no significant correlations
between plasma levels of VEGF and flt-1 or VEGF and KDR
levels, respectively; we have shown previously (Webb et al,
1998) that flt-1 masks the detection of VEGF in plasma
samples and could result in ‘‘underestimation’’ of the true
level of circulating VEGF.
1Coupes BM, Summers AM, Ralph SA, Short CD, Brenchley
PEC: Increased frequency of the VEGF –460CC genotype in renal
transplant recipients [abstract]. Am J Trans 2:413, 2002
2Summers AM, Brenchley PEC, Morgan L, Baker PN: Association
of VEGF þ 405 GG polymorphism with pre-eclampsia [abstract].
J Soc Gynecol Invest 9:80, 2002
3Summers AM, Ralph SA, Short CD, Brenchley PEC: VEGF
460 CC genotype is associated with the progression towards end
stage renal disease [abstract]. J Am Soc Nephrol 13:260, 2002
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Patients with psoriasis and the 460 CC genotype had
significantly lower plasma levels of flt-1 (p¼0.005; mean,
24.0  9.4) than psoriasis patients with a TC or TT genotype
at the 460 locus.
Discussion
We have found a significant association of the VEGF þ405
CC genotype and C allele for severe psoriasis and onset
between 20 and 40 y of age. In addition, plasma levels of
VEGF and flt-1 are increased in patients with psoriasis,
although levels of KDR are no different from controls.
Cutaneous angiogenesis is important for a variety of
physiologic processes, for example, in the anagen stage of
the hair cycle (Mecklenburg et al, 2000). However, a
sustained and significant increase in new blood vessel
formation can be seen in cutaneous disease; for instance,
angiogenesis occurs in primary and metastatic cutaneous
malignant melanoma (Hubler and Wolf, 1976; Srivastava
et al, 1988; Marcoval et al, 1997) rosacea, and psoriasis
(Creamer and Barker, 1995). Epidermal keratinocytes
appear to be the main source of agonists for physiologic
and pathologic cutaneous angiogenesis (Malhotra et al,
1989). VEGF, a permeability-enhancing factor in the early
stages of angiogenesis and an endothelial-cell-specific
mitogen, appears to be both constitutively expressed in
skin and upregulated in conditions where active neovascu-
larization is occurring (Brown et al, 1992; Ballaun et al, 1995;
Weninger et al, 1996).
VEGF is over expressed by keratinocytes in the clinically
involved and the uninvolved skin of patients with stable,
chronic plaque psoriasis (Detmar et al, 1994). Previously it
has been shown that plasma levels of VEGF are elevated in
patients with erythroderma, compared with normal control
subjects (Creamer et al, 1996). In chronic plaque psoriasis
we have previously reported a correlation between levels of
VEGF in plaques of psoriasis, PASI, and levels of VEGF in
peripheral blood (Bhushan et al, 1999). Patients with
generalized pustular psoriasis or a psoriasis PASI of greater
than 30 have been reported as having significantly higher
levels of plasma VEGF compared with patients with a PASI
Table II. Observed frequencies for the –460 VEGF gene polymorphism
within a population of type 1 psoriasis patients (n¼ 56) and healthy controls (n¼ 101)a
Controls
(n¼ 101)
Psoriasis
(n¼137)
Mild/moderate
psoriasis (n¼ 65)
Severe psoriasis
(n¼ 72)
Psoriasis onset before
age 20 (n¼ 81)
Psoriasis onset between
age 20 and 40 (n¼ 56)
Genotype
CC 21 (20.8) 21 (15) 7 (11) 14 (19) 18 (22) 3 (5)b
CT 60 (59.4) 74 (54) 39 (60) 35 (49) 37 (46) 37 (66)c
TT 20 (19.8) 42 (31) 19 (29) 23 (32) 26 (32) 16 (29)
Allele
C 102 (50.5) 116 (42.3) 53 (40.8) 63 (43.8) 73 (45.1) 43 (38.4)
T 100 (49.5) 158 (57.7) 77 (59.2) 81 (56.2) 89 (54.9) 69 (61.6)
aData are presented as number (%). There is significantly reduced frequency of the CC genotype for patients with psoriasis onset between age 20 and
age 40 compared to healthy controls (column 1 vs. column 6) and significantly decreased frequency of the CC genotype with significantly increased
frequency of the CT genotype for patients with psoriasis onset between age 20 and age 40 compared to those with onset before age 20 (column 5 vs.
column 6).
bp¼ 0.02; p¼ 0.01.
cp¼ 0.03.
Table I. Observed frequencies for the þ 405 VEGF gene polymorphism
within a population of type 1 psoriasis patients and healthy controlsa
Controls
(n¼ 102)
Psoriasis
(n¼137)
Mild/moderate
psoriasis
(n¼65)
Severe psoriasis
(n¼ 72)
Psoriasis
onset before
age 20 (n¼81)
Psoriasis onset
between age
20 and 40 (n¼56)
Genotype
GG 47 (46) 50 (36) 26 (40) 24 (33) 32 (40) 18 (32)
GC 48 (47) 67 (49) 32 (49) 35 (49) 41 (51) 26 (46)
CC 7 (7) 20 (15) 7 (11) 13 (18)b 8 (10) 12 (21)c
Allele
G 142 (69.6) 167 (60.9) 84 (64.6) 83 (57.6) 105 (64.8) 62 (55.4)
C 62 (30.4) 107 (39.1) 46 (35.4) 61 (42.3)d 57 (35.2) 50 (46.6)c
aData are presented as number (%). There is significantly increased frequency of the CC genotype and the C allele for patients with severe psoriasis
(column 1 vs. column 4) and psoriasis onset between age 20 and age 40 compared to healthy controls (column 1 vs. column 6).
bp¼ 0.04.
cp¼ 0.02.
dp¼ 0.03.
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of less than 30 and that generalized pustular psoriasis is
accompanied by pathologic proteinuria (Creamer et al,
2002) indicative of enhanced vascular permeability. Never-
theless, in our patient group, we found no correlation
between clinical severity of disease and levels of VEGF in
plasma, although virtually all our psoriasis patients had
elevated levels of VEGF compared with a normal control
population. We observed a lower mean plasma VEGF level
in patients with psoriasis than that published previously
(Creamer et al, 2002). This discrepancy could have occurred
owing to: (1) the difference in choice of subtypes of
psoriasis, that is, chronic plaque psoriasis in the current
study versus pustular or erythrodermic psoriasis; (2) a
difference in spectrum of psoriasis severity; and (3) our
exclusion of patients with psoriatic arthropathy on the basis
of reported elevations in plasma VEGF levels in inflamma-
tory arthritis. We did not address whether conventional
psoriasis treatments influence plasma levels of either VEGF
or its receptors, although it has been reported (Creamer
et al, 2002) that patients with moderate/severe or severe
psoriasis have plasma VEGF levels which are significantly
increased during relapse of psoriasis compared with
remission.
As we learn more about the immunogenetics of psoriasis
it is apparent, with seven psoriasis susceptibility loci so far
described, that psoriasis is polygenic (Elder et al, 2001).
There are, perhaps, several genotypically different but
phenotypically similar forms of chronic plaque psoriasis.
These subsets may be characterized by different triggers,
disease severity and age of onset. For instance, a promoter
polymorphism in the gene encoding TNF-a is associated
with early-onset (at or before age 40) psoriasis in men
(Reich et al, 2002). The þ405 CC genotype in patients with
psoriasis would appear to confer a tendency to develop
severe disease with increased susceptibility to disease
onset between the ages of 20 and 40 y. Furthermore, in view
of the relative cytogenetic proximity of the VEGF gene with
the MHC the possibility that the observed associations may
be due to linkage disequilibrium between the VEGF
polymorphisms and HLA-Cw6 was investigated—there
was no linkage disequilibrium observed between either of
the VEGF polymorphisms studied and HLA-Cw6. The þ405
G ! C SNP may therefore be a significant factor in the
control of disease severity and phenotypic expression in
psoriasis. In the future, it is possible that determination of
VEGF gene polymorphisms may be used as a prognostic
factor for psoriasis severity.
It is possible that the þ405 G ! C SNP may exert
significant functional control over VEGF expression in
psoriasis. However, no significant association was found
between either the þ405 or the 460 genotype and
plasma levels of VEGF in our patients. This may be due to
the primary assay used being affected by circulating soluble
receptor. We have previously demonstrated that in VEGF-
specific ELISA assays, addition of flt-1 to serum containing
a high concentration of VEGF reduced the detected level
with a clear dose response, that is, nondetection of VEGF-
flt-1 complexes (Webb et al, 1998). Alternative analyses
such as Western blotting would probably be unlikely to be
sensitive enough for detection of receptor or protein.
Further study is required to explain whether genetic
variability within the VEGF gene has any measurable impact
on VEGF protein expression. It is possible that the 460 C/
þ 405 C haplotype, which is very rare in the normal popu-
lation (1 in 230 chromosomes analyzed; Watson et al, 2000),
could represent a disease-associated haplotype in psoriasis
and correlate with VEGF plasma levels. One of the other
SNPS, through tight linkage disequilibrium, may be respon-
sible for the observed association with psoriasis and we are
therefore further investigating this area of the VEGF gene.
Flt-1 is a receptor tyrosine kinase which is expressed in
two forms (Kendall and Thomas, 1993; Kendall et al, 1996):
a full-length, membrane-bound receptor capable of trans-
ducing signal, and a truncated, soluble receptor capable of
sequestering ligand or dimerizing with full-length receptor
and preventing signal transduction. KDR is also a receptor
tyrosine kinase—both receptors are almost exclusively
expressed within endothelial cells and preferentially within
proliferating endothelium. VEGF, flt-1, and KDR represent a
regulatory system essential for both normal and pathologic
angiogenesis. High levels of flt-1 reportedly occur in the
plasma during pregnancy and in patients with essential
hypertension (Clark et al, 1998; He et al, 1999; Belgore et al,
2001a, b). Significantly lower levels have been observed in
the plasma of patients with cardiovascular disease and in
smokers (Belgore et al, 2001a, b; Belgore et al, 2000). Flt-1
has a greater affinity for VEGF than KDR, yet KDR is
phosphorylated approximately 10-fold more efficiently upon
ligand binding. Observations suggest that flt-1 functions to
limit VEGF/KDR-mediated angiogenesis (Waltenberger et al,
1994; Fong et al, 1995; Shalaby et al, 1995; Hiratsuka et al,
1998; Bussolati et al, 2001). There is evidence, however,
that the tyrosine kinase domain of flt-1 does play an
angiogenic role. Induced flt-1/KDR heterodimers can
transduce signal (Huang et al, 2001). VEGF-induced nitric
oxide release appears to be mediated by flt-1, and this nitric
oxide release in turn acts as a molecular switch, inhibiting
KDR-mediated proliferation and affecting redifferentiation of
endothelial cells into capillary-like structures (Bussolati et al,
2001). In our study flt-1 levels were significantly elevated in
patients with psoriasis compared with normal controls; by
contrast mean plasma levels of KDR in psoriatics were
comparable with controls. Nevertheless, there was a
significant correlation between plasma flt-1 and KDR levels
in psoriatic patients. In contrast to soluble flt-1, which is an
alternatively spliced cellular product, circulating soluble
KDR is thought to derive from shedding of the receptor from
endothelial cell membrane into the circulation. Thus,
circulating levels of both VEGF receptors could be regarded
as surrogate markers of endothelial cell activity—with
increased endothelial cell turnover likely to result in
shedding of membrane-bound receptor into the plasma.
Overexpression of flt-1 and KDR receptors in dermal
microvascular endothelium has been reported in psoriasis
(Detmar et al, 1994), healing skin wounds (Peters et al,
1993), and delayed hypersensitivity reactions (Brown et al,
1995). It is possible that differential receptor expression may
modulate the biologic effects of VEGF in psoriasis via
transmission of different angiogenic signals to the skin. It
has only recently become possible to measure levels of
KDR in plasma and to our knowledge the current study is
the first to report on soluble KDR levels for any disease.
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A number of antiangiogenesis approaches are being
assessed for the therapy of solid cancers (Brekken et al,
2000); the results of such studies might produce therapeutic
options for angiogenesis-associated skin disease. Currently
a phase II study of bevacizumab (an anti-VEGF monoclonal
antibody) and interferon-a2b is in progress for the treatment
of metastatic malignant melanoma (Chen et al, 2001). There
is particular interest in developing immune-based thera-
peutic approaches that block VEGF function and/or signal-
ing in angiogenesis either by downregulation of VEGF
expression or by interaction with high-affinity receptors on
endothelial cells (Aiello et al, 1995; Presta et al, 1997; Arora
et al, 1999; Fong et al, 1999; Schlaeppi and Wood, 1999).
Recent progress made in the crystallization of protein
kinases has confirmed the ATP-binding domain of tyrosine
kinases as an attractive target for drug design. Two new
compounds for oral administration, currently in clinical trials,
have been developed which are potent inhibitors of both
VEGF receptor kinases with relative selectivity for KDR
receptors—PTK787/ZK222584 and ZD6474 (Hennequin et
al, 2002; Wood, 2000; Traxler et al, 2001). Blockade of the
VEGF/VEGF receptor system has reported utility for VEGF-
dependent pathologic neovascularization and may repre-
sent a future novel, selective approach for the therapy of
psoriasis.
A greater understanding of VEGF gene expression in
psoriasis may lead to better genotypic characterization of
severe disease and allow a pharmacogenetic-based man-
agement approach and could result in the development of
new anti-VEGF therapies for psoriasis.
Materials and Methods
Patients Venous blood samples were collected from 102 normal
controls and 160 patients with type 1 chronic plaque psoriasis, with
a range of clinical severities, recruited from the Psoriasis Clinic at
Hope Hospital (Manchester, UK). Patients were excluded from the
study if they had psoriatic arthropathy, were on systemic treatment
for psoriasis, or were using COX-1 or COX-2 nonsteroidal anti-
inflammatory drugs that can inhibit angiogenesis by blocking
VEGF-induced signal transduction. Psoriasis severity was as-
sessed by the psoriasis area severity index (PASI; Fredriksson and
Pettersson, 1978); a PASI X12 was designated as ‘‘severe’’
psoriasis. Venous blood was collected into ethylenediaminetetraa-
cetic acid blood tubes for DNA extraction and also for plasma
collection. Centrifugation of blood samples and separation and
collection of plasma were performed within 2 h of venepuncture.
Plasma, red cell pellets, and whole-blood samples were stored at
801C until required. The study adhered to the Declaration of
Helsinki Guidelines and was approved by the Salford and Trafford
local research ethics committee and all subjects gave written,
informed consent.
DNA preparation Genomic DNA was isolated from whole blood
and red cell pellets using the QIAamp DNA blood midi kit (Qiagen
Ltd UK, Crawley, West Sussex, UK). Briefly, samples of whole
blood or red cell pellets were mixed with protease and incubated at
701C for 10 min. After being further mixed with absolute ethanol,
the samples were loaded into QIAamp Midi columns and centrifuge
filtered, allowing DNA to remain within the filter but permitting
residual waste to pass through. After two washing steps, the
entrapped DNA was eluted from the filter with distilled water.
Quantification of DNA concentration and purity was performed
using a spectrophotometer (Cecil Series II, Cecil Instruments,
Cambridge, UK).
PCR sequencing PCR was carried out using previously described
primers (Watson et al, 2000) known to amplify the target
polymorphic sequences at positions þ 405 (Genebank Accession
No. RS2010963) and –460 (Genebank Accession No. RS833061) in
the VEGF gene. The primers (50 to 30) used were forward
TGTGCGTGTGGGGTTGAGCG and reverse TACCTGCGGA-
CAGGGCCTGA for the –460 polymorphism and forward ATT-
TATTTTTGCTTGCCATT and reverse GTCTGTCTGTCTGTCCGTCA
for the þ 405 polymorphism. This generated PCR products of 304
and 175 bp, respectively. PCR amplification was performed in a
total reaction volume of 20 mL with 100 ng of DNA, PCR buffer—
16.6 mM ammonium sulfate, 67 mM Tris-HCl (pH 8.0), 85 mg per
mL bovine serum albumin, 0.5 mM of each primer, 10% dimethyl
sulfoxide, 0.75 mM of each deoxynucleoside triphosphate, and 0.5
units Taq polymerase, with varying concentrations of Mg, 5 mM for
the –460 polymorphism and 4 mM for the þ 405 polymorphism. A
geneAmp PCR system 9700 (Applied Biosystems, Foster City, CA)
was used. Thermal cycling conditions consisted of an initial
denaturation step at 941C for 3 min followed by 32 cycles for the
460 polymorphism at 941C for 1 min (denaturation), 601C for 1
min (annealing step), and 721C for 1 min (extension) and 32 cycles
for the þ 405 polymorphism at 941C for 1 min (denaturation), 551C
for 1 min (annealing step), and 721C for 1 min (extension) with a
final extension step for both polymorphisms at 721C for 5 min. For
both polymorphisms, the presence of PCR product was assessed
by electrophoresing 5 mL of PCR product and 2 mL of loading buffer
with a 100-bp DNA ladder (Life Technologies, Paisley, UK) in a 2%
agarose gel stained with ethidium bromide.
Restriction fragment length polymorphism typing PCR product
(15 mL) was digested with the appropriate restriction enzyme, BstUI
(New England Biolabs (UK) Ltd, Hitchin, Hertfordshire, UK) for the
460 polymorphism and BsmFI (New England Biolabs) for the
þ 405 polymorphism overnight at the recommended temperature
(601C for the 460 polymorphism and 651C for the þ 405
polymorphism) and the digested DNA fragments were analyzed
on 3% 1  TBE agarose gels (Fig 1).
Figure1
PCR-restriction fragment length polymorphism analysis of the
VEGF gene þ405 polymorphism. Lane 1, a 100-bp DNA ladder; lane
3, CC genotype; lane 4, GG genotype; lanes 2 and 5, CG genotype.
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HLA-Cw6 polymerase chain reaction sequence-speciﬁc ty-
ping The Cw6 genotyping was performed by PCR sequence-
specific typing. Primers, sense TACTACAACCAGAGCGAGGA and
antisense GGTCGCAGCCATACATCCA, specific for Cw6 were
used, generating a PCR product of 297 bp. The primers were
used at a final concentration of 1.0 mM. A pair of control primers
C1P1 and C1P2, sense GCCTTCCCAACCATTCCCTTA and anti-
sense GTCCATGTCCTTCCTGAAGCA, amplifying a 1060-bp frag-
ment of the human growth hormone gene (GH2) were added to
each Cw6 primer mix to identify failed PCR reactions. The control
primers were used at a final concentration of 0.1 mM. Plate
preparation, PCR conditions, and visualization/interpretation of
results were as previously described by our laboratory for short-
form HLA-DP typing (Davidson and Poulton, 2001).
Determination of plasma levels of VEGF, ﬂt-1, and KDR Plasma
levels of VEGF protein and the receptors flt-1 and KDR were
measured using a specific Quantikine ELISA (R & D Systems,
Abingdon, UK). Briefly, plasma samples and standards were added
in assay diluent to precoated wells and incubated for 2 h at room
temperature. After a standard washing step, anti-VEGF, anti-flt-1,
or an anti-KDR conjugate was added to each well and incubated
for 2 h at room temperature. After an additional washing step,
substrate solution was added to each well for 25 to 30 min, after
which a ‘‘stop’’ solution was added and the plate read on a
ThermoMax plate reader (Molecular Devices, Sunnyvale CA) at 450
nm. VEGF, flt-1, and KDR standards were used to ascertain
interplate variability.
Statistical analysis The chi-square test was used to compare
differences in the observed genotype frequencies and in the
detectability of plasma VEGF/flt-1/KDR levels in the patient and
normal populations. The chi-square test was also used to
investigate linkage between the þ 405 or 460 VEGF polymorph-
isms and HLA-Cw6 for patients with psoriasis. One-way ANOVA
was used to assess the relationship between plasma levels of
VEGF/flt-1/KDR and genotype. Graphical methods and correla-
tions were used to assess the relationships between plasma VEGF/
flt-1/KDR levels; po0.05 was considered statistically significant.
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